[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520475":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":26,"overallOfficials":11,"centralContacts":30,"locations":40,"responsibleParty":57,"collaborators":11,"id":59,"slug":11,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":72,"conditions":73,"keywords":11,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline",null,"12 Months",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NA","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":23,"interventionNames":24},"iStent Infinite","EXPERIMENTAL","iStent Infinite Trabecular Micro-Bypass System",[25],"Device: iStent Infinite",[27],{"type":28,"name":21,"description":23,"armGroupLabels":29,"otherNames":11},"DEVICE",[21],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Dari Parizadeh","CONTACT","949-481-0575","dparizadeh@glaukos.com",{"name":37,"role":33,"phone":38,"phoneExt":11,"email":39},"Kerry Stephens","949-481-8057","kstephens@glaukos.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Glaukos Investigator Site","RECRUITING","Cincinnati","Ohio","45242","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-84.51439,39.12711,{"lat":53,"lon":52},[56],{"name":32,"role":33,"phone":11,"phoneExt":11,"email":11},{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100520475",false,"NCT06057051","Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma","A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma","Inclusion Criteria:\n\n* Diagnosis of primary open-angle glaucoma\n* Phakic or pseudophakic\n* Age 35 years or older\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular, angle-closure glaucoma or\n* glaucoma associated with vascular disorders\n* Active corneal inflammation or edema\n* Retinal disorders not associated with glaucoma","ALL","35 Years",{"count":68,"type":69},245,"ESTIMATED","INTERVENTIONAL",[14],"Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment",[74],"Glaucoma","2023-09-26",{"date":77,"type":78},"2023-09-28","ACTUAL",{"date":80,"type":78},"2023-09-01",{"date":82,"type":69},"2027-08",{"name":5,"class":6},1]